References
- Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
- Carrascosa J, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb). 2018;8(2):173–194.
- Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
- Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe; 2019; [cited 2019 Dec 18]. Available from: http://www.gabio.nline.net/Biosimilars/General/Biosimilars-approved-in-Europe
- Egeberg A. Real world SB4 (etanercept biosimilar) use in patients with psoriasis: data from British Association of Dermatologist Biologic Interventions Registry (BADBIR): Abstract #P1839. 27th EADV Congress; Paris, France; 2018.
- Gisondi P, Bianchi L, Conti A, et al. Infliximab biosimilar CTP13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017;177(6):e325–e326.
- Gisondi P, Bianchi L, Calzavara-Pinton P, et al. Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2019;180(2):409–410.
- Pescitelli L, Lazzeri L, Di Cesare A, et al. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. Int J Clin Pharm. 2019;41(1):9–12.
- Ricceri F, Pescitelli L, Lazzeri L, et al. Clinical experience with infliximab biosimilar in psoriasis. Br J Dermatol. 2017;177(6):e347–e348.
- Di Cesare A, Tronconi G, Fastame TM, et al. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2020;33(3):e13435.
- Zheng J. Absolute Psoriasis Area and Severity Index: an additional evaluation for clinical practice. Br J Dermatol. 2017;176(3):576.